CREBBP and EP300 mutations are one of the main pathogenic mechanisms of B cell non-Hodgkin lymphoma (B-NHL) and have a direct impact on the use of drugs targeting acetylation/deacetylation mechanisms [36]. Here, CREBBP is linked to B-cell non-Hodgkin lymphoma.